Search Within

Thoracic Oncology

Formats
  1. Meeting Abstract (1709)
  2. Journal Article (1439)
  3. Review (82)
  4. Editorial (58)
  5. Book Section (35)
  6. Guidelines (25)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3394)
  2. Solid Tumor Oncology Division (3394)
  3. GSK Faculty (1071)
  4. Department of Pathology and Laboratory Medicine (809)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (662)
  6. Human Oncology and Pathogenesis Program (635)

More Groups

People
  1. Mark Kris (872)
  2. Alexander Drilon (637)
  3. Gregory Riely (605)
  4. Charles Rudin (495)
  5. Marc Ladanyi (418)
  6. Matthew Hellmann (412)

More People

Years
  1. 2025 (114)
  2. 2024 (271)
  3. 2023 (273)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (703)
  2. Journal of Thoracic Oncology (517)
  3. Annals of Oncology (278)
  4. Clinical Cancer Research (158)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (782)
  2. Elsevier Inc. (738)
  3. American Association for Cancer Research (386)
  4. Oxford University Press (352)
  5. Nature Publishing Group (156)
  6. Elsevier Science, Inc. (79)

More Publishers

Results (3394)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion)
    Meeting Abstract

    Baena Espinar, J.; Torri, V.; Whisenant, J.; Hirsch, F. R.; Rogado, J.; de Castro Carpeño, J.; Halmos, B.; Ceresoli, G. L.; Gomez Rueda, A.; Tiseo, M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Survival benefits of larotrectinib in an integrated dataset of patients with TRK fusion cancer
    Meeting Abstract

    McDermott, R.; van Tilburg, C. M.; Farago, A. F.; Kummar, S.; Tan, D. S. W.; Albert, C. M.; Berlin, J.; Lassen, U. N.; Doz, F.; Geoerger, B.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Larotrectinib treatment of advanced TRK fusion thyroid cancer
    Meeting Abstract

    Cabanillas, M. E.; Drilon, A.; Farago, A. F.; Brose, M. S.; McDermott, R.; Sohal, D.; Oh, D. Y.; Almubarak, M.; Bauman, J.; Chu, E.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Phase Ib expansion study of adavosertib plus olaparib in patients with extensive-stage or relapsed small cell lung cancer
    Meeting Abstract

    Li, B. T.; Hamilton, E. P.; Wang, J. S.; Falchook, G. S.; Oza, A. M.; Rodrigo Imedio, E.; Kumar, S.; Mugundu, G. M.; De Bruin, E.; Spigel, D. R.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) in KEYNOTE-604: Pembrolizumab (pembro) or placebo added to etoposide and platinum (EP) as first-line therapy for ES-SCLC
    Meeting Abstract

    Kim, H. R.; Awad, M. M.; Navarro, A.; Gottfried, M.; Peters, S.; Csoszi, T.; Cheema, P. K.; Rodriguez-Abreu, D.; Wollner, M.; Yang, J. C. H.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Integrated safety analysis of tazemetostat (TAZ) 800 mg BID in adult patients (pts) with hematologic and solid tumors
    Meeting Abstract

    Morschhauser, F.; McKay, P.; Salles, G.; Stacchiotti, S.; Schwartz, G. K.; Tilly, H.; Zauderer, M. G.; Fennell, D. A.; Jones, R. L.; Schöffski, P.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Preliminary safety and activity of CLN-081 in NSCLC with EGFR exon 20 insertion mutations (Ins20)
    Meeting Abstract

    Piotrowska, Z.; Nguyen, D.; Koczywas, M.; Tchekmedyian, N.; Clancy, M. S.; Witter, D.; Page, A.; Zawel, L.; Yu, H. A.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) in patients (pts) with NSCLC harboring MET exon 14 skipping (METex14) treated with tepotinib
    Meeting Abstract

    Garassino, M. C.; Le, X.; Kowalski, D. M.; Migliorino, M. R.; Senellart, H.; Fuentes Pradera, J.; Walling, R.; Kato, T.; Thomas, M.; Smit, E. F.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • LIBRETTO-431: Selpercatinib in treatment (Tx)-naive patients with RET fusion-positive (RET+) non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Loong, H. H. F.; Goto, K.; Elamin, Y. Y.; Solomon, B.; Santini, F. C.; Soldatenkova, V.; Sashegyi, A.; Bence Lin, A.; Lin, B. K.; Wolf, J.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Efficacy and safety of entrectinib in locally advanced/metastatic ROS1 fusion-positive NSCLC: An updated integrated analysis
    Meeting Abstract

    Krebs, M. G.; De Braud, F.; Siena, S.; Drilon, A.; Doebele, R. C.; Patel, M. R.; Cho, B. C.; Liu, S. V.; Ahn, M. J.; Chiu, C. H.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save